Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

PURPOSE: Anlotinib, a tyrosine kinase inhibitor (TKI) has been in clinical application to inhibit malignant cell growth and lung metastasis in osteosarcoma (OS). However, a variety of drug resistance phenomena have been observed in the treatment. We aim to explore the new target to reverse anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiuhui, Chen, Chenglong, Sun, Kunkun, Shi, Qianyu, Wang, Boyang, Huang, Yi, Ren, Tingting, Tang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315670/
https://www.ncbi.nlm.nih.gov/pubmed/37404767
http://dx.doi.org/10.3389/fonc.2023.1192472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315670/
https://www.ncbi.nlm.nih.gov/pubmed/37404767
http://dx.doi.org/10.3389/fonc.2023.1192472

Ejemplares similares